1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Rising Tide Lifts Many Ships In Wake Of Eisai/Biogen’s Lecanemab Readout

Firms Boosted Regardless Of Alzheimer’s Drugs’ Mechanisms

 
• By Mandy Jackson

Eisai and Biogen had double-digit stock price gains based on the positive Phase III readout for lecanemab. The good news also lifted competitors Lilly and Roche as well as earlier-stage Alzheimer’s drug developers.

Boats competing in a sailing regatta in the Mediterranean Sea off Turkey
Lilly and Roche, neck-and-neck with Eisai and Biogen, also rose on the Clarity AD data • Source: Shutterstock

Eisai Co., Ltd. and Biogen, Inc. shocked investors and just about everyone else who has tracked the progress of amyloid-targeting therapies for Alzheimer’s disease when they reported what appear to be the first unequivocal Phase III success for the field. Both companies saw their stock prices surge in the US as a result and other Alzheimer’s drug developers, regardless of the mechanism of action for their candidates, saw their valuations increase as well.

Eisai said when it and Biogen reported top-line results for the amyloid protofibril-clearing antibody lecanemab from the Phase III Clarity AD clinical trial on the morning of 28 September in Japan (the evening of 27 September in the US) that the data prove the hypothesis that clearing amyloid from the brains of Alzheimer’s patients can slow the progression of the neurodegenerative disease

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

More from R&D

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.